A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes - PubMed (original) (raw)
Meta-Analysis
doi: 10.4088/JCP.08m04902pur. Epub 2009 Dec 29.
Affiliations
- PMID: 20051220
- DOI: 10.4088/JCP.08m04902pur
Meta-Analysis
A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes
Stephen V Faraone et al. J Clin Psychiatry. 2010 Jun.
Abstract
Objectives: Medications used to treat attention-deficit/hyperactivity disorder (ADHD) in adults have been well researched, but comparisons among drugs are hindered by the absence of direct comparative trials. Our objectives were to (1) estimate the effect size of the medications used to treat adult ADHD, (2) determine if differences in the designs of studies confound comparisons of medication efficacy, (3) quantify the evidence for differences in effect sizes among medications, and (4) see if features of study design influence estimates of efficacy.
Data sources: The following search engines were used: PubMed, Ovid, ERIC, CINAHL, MEDLINE, PREMEDLINE, the Cochrane database, e-psyche, and Social Sciences Abstracts. Presentations from the American Psychiatric Association and American Academy of Child and Adolescent Psychiatry meetings were reviewed.
Study selection: A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD in adults published in English after 1979. Only trials that used DSM-III, -III-R, or -IV ADHD criteria and followed subjects for > or = 2 weeks were selected.
Data extraction: Meta-analysis regression assessed the influence of medication type and study design features on medication effects.
Results: Nineteen trials met criteria and were included in this meta-analysis. These trials studied 13 drugs using 18 different outcome measures of hyperactive, inattentive, or impulsive behavior. After trials were stratified on the class of drug studied (short-acting stimulant vs long-acting stimulant vs nonstimulant), significant differences in effect size were observed between stimulant and nonstimulant medications (P = .006 and P = .0001, respectively, for short- and long-acting stimulants vs nonstimulants), but the effect for short-acting stimulants was not significant after correcting for study design features. The effect sizes for each drug class were similar in magnitude to what we previously reported for medication treatment studies of children with ADHD. We found significant heterogeneity of effect sizes for short-acting stimulants (P < .001) but not for other medication groups.
Conclusions: Although both stimulant and nonstimulant medications are effective for treating ADHD in adults, stimulant medications show greater efficacy for the short durations of treatment characteristic of placebo-controlled studies. We found no significant differences between short- and long-acting stimulant medications. Study design features vary widely among studies and can confound indirect comparisons unless addressed statistically as we have done in this study.
2010 Physicians Postgraduate Press, Inc.
Similar articles
- Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S. Christensen L, et al. Curr Med Res Opin. 2010 Apr;26(4):977-89. doi: 10.1185/03007991003673617. Curr Med Res Opin. 2010. PMID: 20178404 - Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R. Spencer TJ, et al. Clin Ther. 2006 Feb;28(2):266-79. doi: 10.1016/j.clinthera.2006.02.011. Clin Ther. 2006. PMID: 16678648 Clinical Trial. - Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
Biederman J, Pliszka SR. Biederman J, et al. J Pediatr. 2008 Mar;152(3):394-9. doi: 10.1016/j.jpeds.2007.07.052. Epub 2007 Oct 24. J Pediatr. 2008. PMID: 18280848 - Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL. Findling RL. Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Clin Ther. 2008. PMID: 18555941 Review. - Attention-deficit-hyperactivity disorder: an update.
Dopheide JA, Pliszka SR. Dopheide JA, et al. Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Pharmacotherapy. 2009. PMID: 19476419 Review.
Cited by
- Polygenic transmission and complex neuro developmental network for attention deficit hyperactivity disorder: genome-wide association study of both common and rare variants.
Yang L, Neale BM, Liu L, Lee SH, Wray NR, Ji N, Li H, Qian Q, Wang D, Li J, Faraone SV, Wang Y; Psychiatric GWAS Consortium: ADHD Subgroup. Yang L, et al. Am J Med Genet B Neuropsychiatr Genet. 2013 Jul;162B(5):419-430. doi: 10.1002/ajmg.b.32169. Epub 2013 May 31. Am J Med Genet B Neuropsychiatr Genet. 2013. PMID: 23728934 Free PMC article. - Does attention-deficit hyperactivity disorder medication reduce entrepreneurship?
Peltonen J, Johansson E, Wincent J. Peltonen J, et al. Health Econ. 2020 Sep;29(9):1071-1077. doi: 10.1002/hec.4120. Epub 2020 Jun 22. Health Econ. 2020. PMID: 32567214 Free PMC article. - A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD.
Kollins SH, English JS, Itchon-Ramos N, Chrisman AK, Dew R, O'Brien B, McClernon FJ. Kollins SH, et al. J Atten Disord. 2014 Feb;18(2):158-68. doi: 10.1177/1087054712440320. Epub 2012 Apr 16. J Atten Disord. 2014. PMID: 22508760 Free PMC article. Clinical Trial. - Complex prospective memory in adults with attention deficit hyperactivity disorder.
Fuermaier AB, Tucha L, Koerts J, Aschenbrenner S, Westermann C, Weisbrod M, Lange KW, Tucha O. Fuermaier AB, et al. PLoS One. 2013;8(3):e58338. doi: 10.1371/journal.pone.0058338. Epub 2013 Mar 6. PLoS One. 2013. PMID: 23484020 Free PMC article. - Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial.
Atkins C, Jones A, Clark AB, Stockl A, Fordham R, Wilson AM. Atkins C, et al. BMJ Open Respir Res. 2021 May;8(1):e000814. doi: 10.1136/bmjresp-2020-000814. BMJ Open Respir Res. 2021. PMID: 34020962 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous